Trials / Completed
CompletedNCT00258908
Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan
Immunogenicity and Safety of ADACEL™ (TdcP Vaccine) as Fifth Dose in Children 6-8 Years of Age.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- Sanofi Pasteur, a Sanofi Company · Industry
- Sex
- All
- Age
- 6 Years – 8 Years
- Healthy volunteers
- Accepted
Summary
To assess the immunogenicity profile of ADACEL™, Tetanus and Diphtheria Toxoids Adsorbed combined with Component Pertussis Vaccine (TdcP Vaccine) one month after administration. To describe the safety profile of ADACEL™ (TdcP Vaccine) when given as a fifth dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Diphteria, tetanus, and Acellular Pertussis vaccine | 0.5 mL, Intramuscular |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2005-11-28
- Last updated
- 2016-04-14
- Results posted
- 2009-06-08
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00258908. Inclusion in this directory is not an endorsement.